Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Adoptive T Cell Therapy / CAR-T & Multiple Myeloma (MM) / Plasmocytoma

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Adoptive T Cell Therapy / CAR-T is now an established treatment class for relapsed/refractory multiple myeloma, with B-cell maturation antigen (BCMA)-directed products showing high activity and moving into earlier lines of therapy. For plasmacytoma or plasmablastic/extramedullary myeloma, the evidence is much more limited and is mainly based on small retrospective series, abstracts, and case reports rather than standard guideline-level data
Füchsl & Krackhardt 2022 Cells 11(3): 410
Sheykhhasan et al. 2024 Cancer Gene Ther 31: 667-686
Jin et al. 2025 Hematology 30(1): 2481555

In recent years, immunotherapy for the treatment of [Multiple Myeloma (MM) / Plasmocytoma](brain://yorR1fz0oEK-YjkFd1…

References (Sources)

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
Füchsl & Krackhardt 2022 Cells 11(3): 410
Review
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
Jin et al. 2025 Hematology 30(1): 2481555
CAR T therapies in multiple myeloma: unleashing the future
Sheykhhasan et al. 2024 Cancer Gene Ther 31: 667-686
Review
Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma
Frigault et al. 2022 J Clin Oncol 40: suppl 16 abstr 8003
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
Shah et al. 2020a
Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity
Globerson Levin et al. 2020 Cancer Immunol. Res 8: 1485

AI Chat

7/1/2026

Chat with our artificial intelligence: